X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

    Neurodevelopmental Issue Leads To Testicular Cancer Risk

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

    The UK begins the biggest ever immunization program

    New Approach Brought By Singapore For Pneumococcal Vaccines

    New Gestational Diabetes Alliance By Birmingham University

    New Gestational Diabetes Alliance By Birmingham University

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    Omya enhances supply of active pharmaceutical ingredients

    Omya enhances supply of active pharmaceutical ingredients

    Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

    Mix of Modified Antibodies Offer Strong Effect On SARS-CoV-2

    Singapore Creates Ingestible Capsule For Radiation Track

    New Research Projects For Growth From The Office of The FDA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

    Neurodevelopmental Issue Leads To Testicular Cancer Risk

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

    The UK begins the biggest ever immunization program

    New Approach Brought By Singapore For Pneumococcal Vaccines

    New Gestational Diabetes Alliance By Birmingham University

    New Gestational Diabetes Alliance By Birmingham University

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    Omya enhances supply of active pharmaceutical ingredients

    Omya enhances supply of active pharmaceutical ingredients

    Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

    Mix of Modified Antibodies Offer Strong Effect On SARS-CoV-2

    Singapore Creates Ingestible Capsule For Radiation Track

    New Research Projects For Growth From The Office of The FDA

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

Content Team by Content Team
27th April 2023
in Drug Development, News
Tumors Can Get Destroyed By Bacteria-Aid To Immune System

R21/Matrix-M happens to have a saponin-based adjuvant, Matrix-M, which goes on to enhance the immune response, thereby making it more viable and also durable.

It is well to be noted that the adjuvant stimulates the entry of the antigen-presenting cells within the injection site and also goes on to elevate the antigen presentations within the local lymph nodes. Apparently, this technology has been used pretty accurately in the COVID-19 vaccine developed by Novavax.

In case of phase II trials, malaria vaccine showed high levels of efficacy and safety in children who went on to receive a booster dose a year after a primary three-dosage course.

Significantly, the booster dose of R21/Matrix-M continued to be in sync with the WHO’s Malaria Vaccine Technology Roadmap objective of a vaccination that possesses a minimum 75% rate of efficacy.

The 2021 result from the Phase IIb trial followed it, which reported that R21/Matrix-M showed a high level of efficacy of almost 77%. According to the current data, the ongoing Phase III trial, which went on to enrol 4800 kids, showed high efficacy levels as well as a reassuring safety profile. More inferences from the R21/Matrix-M vaccine trials are anticipated to come later in 2023.

The R21/Matrix-M malaria vaccine, which was developed by the University of Oxford, has been given the go-ahead to be used in Ghana in the middle of April and is also authorised to be used in Nigeria on April 17.

The malaria vaccine approval in Ghana was the first in the world. It was granted full national licensure by the Ghanian Food and Drugs Authority and was authorised to be used for children between 5 months and 36 months. Apparently, this age group happens to be at the highest risk of malarial deaths.

As per Adrian Hill, the chief investigator of the R21/Matrix-M programme as well as the director of Oxford University’s Jenner Institute at the Nuffield Department of Medicine, this feat marks the end of 30 years of Oxford’s malaria vaccine analysis. He added that Ghana’s regulatory approval happens to be a vital step in helping to reduce the more than half a million deaths that occur every year.

As per Professor Hill, the collaboration with the vaccine’s manufacturer held the key to accomplished and large-scale manufacturing as well as rapid development. According to the manufacturer, they have the capacity to manufacture more than 200 million doses.

Previous Post

United Cargo - after Opticooler RAP, now also Opticooler RKN certified

Next Post

Neurodevelopmental Issue Leads To Testicular Cancer Risk

Related Posts

Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment
News

Neurodevelopmental Issue Leads To Testicular Cancer Risk

27th April 2023
DoKaSch Temperature Solutions and Japan Airlines sign Master Rental Agreement
News

United Cargo – after Opticooler RAP, now also Opticooler RKN certified

26th April 2023
The UK begins the biggest ever immunization program
News

New Approach Brought By Singapore For Pneumococcal Vaccines

26th April 2023
New Gestational Diabetes Alliance By Birmingham University
Drug Development

New Gestational Diabetes Alliance By Birmingham University

20th April 2023
A first-class conference line-up announced ahead of Chemspec Europe 2023
Drug Development

A first-class conference line-up announced ahead of Chemspec Europe 2023

20th April 2023
Omya enhances supply of active pharmaceutical ingredients
Drug Development

Omya enhances supply of active pharmaceutical ingredients

20th April 2023
Next Post
Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

Neurodevelopmental Issue Leads To Testicular Cancer Risk

Latest News

Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment
News

Neurodevelopmental Issue Leads To Testicular Cancer Risk

27th April 2023
Tumors Can Get Destroyed By Bacteria-Aid To Immune System
Drug Development

Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

27th April 2023
DoKaSch Temperature Solutions and Japan Airlines sign Master Rental Agreement
News

United Cargo – after Opticooler RAP, now also Opticooler RKN certified

26th April 2023
The UK begins the biggest ever immunization program
News

New Approach Brought By Singapore For Pneumococcal Vaccines

26th April 2023
Press Statements

Aptar Digital Health and Healint Announce Innovative Collaboration for Central Nervous System and Immune System Conditions

25th April 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In